ArticleBMC bioinformatics2023
Multimodal hybrid convolutional neural network based brain tumor grade classification.
Article in BMC bioinformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 25 citations in OpenAlex.
- Hybrid Decision-Level Fusion of CNN-Based Deep and Handcrafted Features for Colon Cancer Classification.Journal of imaging · 2026Article
- MM FD ConvFormer multimodal frequency aware deformable CNN transformer network for robust brain tumor classification.Scientific reports · 2026Article
- Precision lung cancer screening from CT scans using a VGG16-based convolutional neural network.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An abnormal growth or fatty mass of cells in the brain is called a tumor. They can be either healthy (normal) or become cancerous, depending on the structure of their cells. This can result in increased pressure within the cranium, potentially causing damage to the brain or even death. As a result, diagnostic procedures such as computed tomography, magnetic resonance imaging, and positron emission tomography, as well as blood and urine tests, are used to identify brain tumors. However, these methods can be labor-intensive and sometimes yield inaccurate results. Instead of these time-consuming methods, deep learning models are employed because they are less time-consuming, require less expensive equipment, produce more accurate results, and are easy to set up. In this study, we propose a method based on transfer learning, utilizing the pre-trained VGG-19 model. This approach has been enhanced by applying a customized convolutional neural network framework and combining it with pre-processing methods, including normalization and data augmentation. For training and testing, our proposed model used 80% and 20% of the images from the dataset, respectively. Our proposed method achieved remarkable success, with an accuracy rate of 99.43%, a sensitivity of 98.73%, and a specificity of 97.21%. The dataset, sourced from Kaggle for training purposes, consists of 407 images, including 257 depicting brain tumors and 150 without tumors. These models could be utilized to develop clinically useful solutions for identifying brain tumors in CT images based on these outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.